DA-DKP
Knee Osteoarthritis
Ampio Pharmaceuticals. Inc.Small moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
21 Active assets in the Knee Osteoarthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPIVACAINE Poznan University of Medical Sciences | Phase 4 | BBB |
DEXAMETHASONE Poznan University of Medical Sciences | Phase 4 | BB |
CHONDROITIN SULFATE Azienda di Servizi alla Persona di Pavia | Phase 4 | BB |
Bxcl501 Poznan University of Medical Sciences | Phase 4 | BB |
DICLOFENAC Brigham and Women's Hospital | Phase 4 | BB |
View all 39 →
Same molecule, other indications
DA-DKP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →